185 related articles for article (PubMed ID: 35507692)
1. Daratumumab in AL amyloidosis.
Wechalekar AD; Sanchorawala V
Blood; 2022 Dec; 140(22):2317-2322. PubMed ID: 35507692
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G; Milani P; Malavasi F; Merlini G
Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
[TBL] [Abstract][Full Text] [Related]
3. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
[TBL] [Abstract][Full Text] [Related]
4. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
Godara A; Palladini G
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
8. Future Developments in Light Chain Amyloidosis Management.
Rodriguez M; Lenihan D; Merlini G
Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
Popkova T; Hajek R; Jelinek T
Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
[TBL] [Abstract][Full Text] [Related]
12. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
[TBL] [Abstract][Full Text] [Related]
14. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
[No Abstract] [Full Text] [Related]
16. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Kaufman GP; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood; 2017 Aug; 130(7):900-902. PubMed ID: 28615223
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
19. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
20. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
